Editas Medicine Announces Third Quarter 2024 Results and Business Updates
November 04, 2024 07:30 ET
|
Editas Medicine, Inc.
Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine’s proprietary targeted LNP in a key step to developing a novel...
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
October 22, 2024 07:00 ET
|
Editas Medicine, Inc.
Achieved in vivo preclinical proof of concept of hematopoietic stem and progenitor cell editing by utilizing Editas Medicine’s proprietary targeted LNP as a key step forward toward developing a novel...
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
October 21, 2024 16:30 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant...
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
October 18, 2024 16:01 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a Company-sponsored webinar...
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
October 03, 2024 18:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced the sale of certain future license fees and other...
Editas Medicine to Participate in Upcoming Investor Conferences
August 28, 2024 09:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following...
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
August 07, 2024 07:00 ET
|
Editas Medicine, Inc.
On track to present additional clinical data from the RUBY trial and the EdiTHAL trial by year-end In vivo preclinical proof-of-concept for an undisclosed indication on-track by year-end Strong...
Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
July 31, 2024 07:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast...
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
June 14, 2024 03:01 ET
|
Editas Medicine, Inc.
All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization of total hemoglobin with a mean within...
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
June 14, 2024 03:00 ET
|
Editas Medicine, Inc.
All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel) infusion Reni-cel was...